Further studies will allow to investigate whether NF-YA splicing signature can improve active surveillance in low-risk PCa or properly classify aggressive cancers erroneously defined as “intermediate” risk on the basis of tumor biopsy, thus avoiding both over- or under-treatment. The gene discussed is NFYA; the disease is neoplasm.